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Summary
IgG extracted from the sera of African adults immune to malaria were injected intravenously
into eight Plasmodium falcipamm-infected nonimmune Thai patients. Clinical and parasitological
improvement was reproducibly obtained in each case. After the disappearance of the transferred
Ig, recrudescent parasites were equally susceptible to the same Ig preparation. High levels of
antibodies to most parasite proteins were detected by Western blots in the receivers' sera (taken
before transfer) as in the donors' Ig, thus indicating that the difference was qualitative rather
than quantitative between donors and receivers. In vitro, the clinicallyeffective Ig had no detectable
inhibitory effect on either penetration or intra-erythrocytec development of the parasite. On the
contrary, they sometimes increased parasite growth. In contrast, these IgG, as the receivers' Ig
collected 4 d aftertransfer, but not those collected before transfer, proved able to exert an antibody-
dependent cellular inhibitory (ADCI) effect in cooperation with normal blood monocytes. Results
were consistent among the seven isolates studied in vitro, as with the recrudescent parasites.
Thus, the results obtained in the ADCI assay correlate closely with clinical and parasitological
observations.
n regions where malaria is hyperendemic, it has been ob-
served that the acute disease is mainly a feature of child-
hood. Though adults can still be infected, they reach after
several years a state of relative resistance. This incomplete,
nonsterilizing immunity, where low grade parasitemia can
be observed and symptoms are usually absent, has been called
premunition (1).
The effector mechanisms mediating premunition against
Plasmodium falciparum blood stages are far from being well
known. Due to the lack ofMHC molecules on RBC, it can
be a priori expected that cytotoxic lymphocytes have little
or no role to play. Conversely, the in vivo effect in humans
of passively transferred African adults' IgG strongly suggests
that antibodies of IgG class are an important component of
acquired immunity (2-4).
Relatively few studies have addressed the question of how
these antibodies mediate protection. From these studies, de-
spite conflicting data, it is nowadays generally accepted that
antibodies inhibit merozoite penetration into erythrocytes.
However, our former studies did not support the hypothesis
that IgG from immune African adults may have a significant
blocking effect on merozoite entry, but rather, suggested that
they act by cooperating with leukocytes (5, 6). Thus, the
mode ofaction of antibodies remains controversial. One im-
portant consequence ofthis situation is an absence ofa univer-
sally accepted assay relevant to protection, and therefore, a
lack of reliable means to select for vaccine candidates by in
vitro methods.
For this and otherreasons, particularly the poorly known
relevance of models, we thought that additional immuno-.
logical investigations in man were required. A recent experi-
ment ofpassive transfer ofIgG in humans gave us the unique
opportunity to perform in parallel an in vitro study using
parasite isolates and antibodies the in vivo interactions ofwhich
were well defined by clinical and parasitological observations.
Materials and Methods
In Vivo Transfer ofImmune IgG.
￿
A set-up allowing us to per-
form in vivo studies under ethically acceptableconditions was de-
signed. A pool of immune African globulins (PIAG)l was prepared
from immune individuals. Since there is no universally accepted
1 Abbreviations used in this paper . ADC, antibody-dependent cellular
inhibition; IFA, indirect fluorescent antibody; NSE, nonspecific esterase;
PIAG, pool of immune African globulins; RESA, ring-infected erythrocyte
surface antigen.
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and donors were selected on clinical andepidemiologicalgrounds.
Allwere adults living in ruralareas wheremalariais holoendemic,
whoexperienced numerous malaria attacks in childhoodandwere
free ofsymptoms andheavyparasitic loads. The detailed procedure
of serum sampling in Africa, safety control studies, IgG extrac-
tion, and Ig administration in P . fakiparum-infected patients is de-
scribed in detail elsewhere (Sabchareun, A., T Burnouf, D. Ouat-
tara, P. Attanah, H. Bouharoun, P Chantavanich, C. Foucault,
T Chongsuphajaisiddbi, and P. Druilhe, manuscript submittedfor
publication). Briefly, sera from 333 African adults were collected
in a rural part of the Ivory Coast and submitted to extensive
screening using all methods available in the present state of the
art. One to threedistinct assays were used to screen for abnormal
hemagglutinins, hemolysins, antibodies to syphilis, HBs antigen,
anti-HBs and c antibodies, and HIV-1 and -2 antibodies. 153 of
the sera were discarded for safety reasons (positivity or doubtful
results in oneor severalofthe above tests).To avoidcontamination
by possibly mislabeled samples, these controls were repeated in sub-
pools of 10 sera, which were finally mixed together. IgG pure
enough forintravenous usewaspreparedundergood manufacturing
practice conditions by an industrial group (Biotransfusion CRTS,
Lille, France), using the Cohn extraction procedure followed by
partial pepsine treatment at pH 4, a method that does not alter
the Fc fragment of IgG (7).
To ensure a safety margin of at least 48 h,'allowing to switch
to drug therapy, receivers ofIgG were chosen amongpatients having
arecrudescent parasitemia afterdrug treatment failure of aprimarily
acutecase. In this situation, where-parasitemia'is progressively in-
creasing but relatively low, symptoms are still relatively mild or
absent, though theywould progressively appear or increase in the
next few days. Indeed,' an increase in symptoms occurred in the
group of40. patients whowere in the same situation of recrudes-
cence after quinine therapy failure, and they served as controls. A
total of eight Thai patients with P. falciparum parasitemia
(5-10,000/mm'), were treated in theHospital for TropicalDisease
(Bangkok, Thailand), by slow intravenous inoculation of theAfrican
IgGpool, one with a20-mg/kg single dose, sixat 100-mg/kgtotal
total dose spread over 3 d (day 0, 20 mg/kg; day 1, 30 rag/kg;
day2, 50 mg/kg),andonewith a200-mg/kgsingle dose. In three
cases, late recrudescent parasitesthat appeared upon follow-up'were
treated with a total dose of 200 mg/kg over 2 d (100 mg/kg/d).
The patients remained underclose medical supervision in thehos-
pital, received Fansimef (an ahtimalarial drug made of a combina-
tion of sulfadoxine-pyrimethamine and mefloquine) before being
discharged, and were followed up at home for 1 yr.
IgG Preparations Used In Vitro.
￿
Samples of PIAG prepared as
described above were obtained before andafterthepartial pepsine
treatment. In addition, we studied IgG from the following sera:
(a) five individual immune Aican adults; (b) eight Thai patients
treated with PIAG, using samples obtained on day 0 before IgG
was transferred andon day4afterinitiating treatment; (c)sixP.fal-
ciparum primary attack cases in French' travellers, who had high
antibody titers but presumably had no clinical protection against
reinfection; (d) five healthy French blood donors with no history
of malaria as normal controls.
IgGwas extracted from the above additional setof sera -by-ion
exchange chromatography on DEAFTrisacryl (IBF, Biotechnics,
Villeneuve-la-Garenne, France) according to the manufacturer's
specifications. The IgG was dialyzed against RPMI 1640, 35 mM
Hepes, 23 mM NaHC05 medium, and concentrated to the ori-
ginal IgG concentration in the serum and sterilized on 0,22-pm
pore size Millex filters (Millipore Continental WaterSystems, Bed-
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ford,MA). Thepresenceandpurity oftheIgGcollected wasascer-
tained in dot blot assays with mAbs specific forhuman IgG, IgM,
or IgA, and with serial serum dilutions in dotblots using atotal
extract of P. falciparum blood stage proteins as antigen and the
original serumas control. IgG from a pool of>1,000 healthy French
blooddonors prepared by theCohn method (CRTS, Lille, France)
was used as control in all antibody-dependent cellular inhibition
(ADCI) assays where the PIRG was tested. Sterile IgGwere kept
at 4°C until use.
Parasites.
￿
P. fakiparumblood stageparasites were isolated from
the Thai patients on day0before starting IgG treatment. One ali-
quot from each isolate was cultured in RPMI plus 10% human
serumas described (8), and theothers were cryopreservedin liquid
nitrogen. Amongtheeight isolates, sevencouldbe adapted to cul-
ture conditions andwere also cryopreserved at various times after
in vitro adaptation. In addition, recrudescent parasites were col-
lected from each patient on day21-29, cultured, andcryopreserved.
Controlcultures were performed with theNF54P.falciparum line,
which is thought to originate from Africa (9). When required,
parasite cultures were synchronized by two Sorbitol treatments at
8-hinterval (10) and, after in vitro maturation, were concentrated
by flotation on plasmagel (11).
Invasion and Growth Inhibition Assays.
￿
P. fakiparum inhibition
assays were performed in duplicates in 96-well plates (Nunc,
Roskilde, Denmark) at a 2% hematocrit. Unless otherwise indi-
cated, therewas no medium replacement during the 18- and48-h
tests. The effect ofpurified IgGon RBC invasion by P. falciparum
merozoites was tested in 18-h cultures initiated with mature
schizonts at 1-2% parasitemia from synchronized cultures. The
direct effect of IgG on P. fakiparum growth was assessed in 48-h
cultures of nonsynchronized parasites at a 0.2-0.5% initial para-
sitemia. In both assays, test and control IgG were added to the
culture medium at 5, 10, and 20% of their original concentration
in thedonorserum. Parasitemia wasestimatedin thin smears from
each well by microscopic examination of >10,000 erythrocytes.
ADCI Assay.
￿
Blood mononuclear cells from healthy French
donors were separatedon Ficoll-Hypaque density gradient (Phar-
macia Fine Chemicals, Uppsala, Sweden) according to the tech-
niqueof My=(12).Thenumber ofmonorytes in thecell suspen-
sion obtained wasestimatedby thenonspecific esterase (NSE) stain
(13). The mononuclear cell suspension (in RPMI) was thereafter
distributed in a 96-well plates at the rate of 2 x 105 monocytes
(NSE+ cells) per well. After a 90-min incubation at 37°C in a 5%
C02-air mixture, nonadherent cells were removed from wells by
washings with RPMI. This method permitted the recovery of
-105 adherent cells per well, among which, >90% were monocytes.
In the wells containing the adherent monocytes, P. fakiparum
asynchronous cultures were added at a ratio of 200 RBC per one
monocyte. The culture medium (RPMI + 10% human serum)
was supplemented with each of the purified IgG to be tested at
10% of their initial concentration in the donor serum (or 5, 10,
20, and 40% for some experiments). Control wells consisted of
(a)culture alone; (b) culture and test IgG without monocytes; (c)
culture and control IgG; and (d)culture, control IgG, and mono-
cytes. Unless otherwisestated, theassayduration was 48 h.Starting
at 0.2-0.5%, parasitaemia generally reached 1-3%.
The specific growth inhibitory index (SGI), which takes into
accountthe possible inhibition inducedby either cellsor antibodies
(IgG) alone, used as controls in each experiment, was calculated
as follows: SGI - 100x [1 - (percent parasitemia with monocyte
andIgG/percent parasitemia with IgG)/(percent parasitemia with
monocyte andcontrol IgG/percent parasitemia with control IgG)].
Antibody Assays.
￿
Western blot analysis was performed using
Monocyte-Antibody Cooperation in Plamodiumfalciparum Malariamature schizonts separated from P.falciparurn cultures by flotation
on plasmagel, which were then washed in RPMI (11). Parasite ex-
tracts from each patient isolate and from NF54 strain were sub-
jected to electrophoresis in a 7.5% polyacrylamide gel containing
SDS (14), and proteins were electroblotted onto nitrocellulose filters
(BA 85; Schleicher& Schnell, Inc., Dassel, FRG) (15). Nitrocellu-
lose strips wereblocked in 5% nonfat mills(Rhgilait, Saint-Martin-
Belle-Roche, France) Tris buffer (50 mM Tris-HCI, pH 8, 0.15 M
NaCl) and incubated with human sera diluted 1:100 in the same
buffer. After washings, the strips were incubated with "SI-labeled
(16) anti-human IgG or IgM (Biosys, Compiegne, France) diluted
1:2,000, washed, and autoradiographed at -70°C. Western blots
were scanned using a scanning densitometre (GS300; Hoefer
Scientific Instruments, San Francisco, CA), areas under each peak
calculated, and were expressed in arbitrary units compared with
a positive control serum run on the same gel.
An indirect fluorescent antibody (IFA) assaywas performed on
thin smears of infected RBC (2-4% parasitaemia) from each pa-
tient isolate, using serial dilutions from 1:200 to 1:102,400 ofeach
serum in PBS (pH 7.4), and FITC-conjugated anti-human IgG
(diluted 1/100) (Nordic Immunology, Tilburg, The Netherlands)
as a second serum. The ring-infected erythrocyte surface antigen
(RESA) IFA was performed as described by Perlmann et al. (17)
using glutaraldehyde-fixed ring-infected erythrocytes from patient
B. In addition, specific malarial antibodies were also measured using
the counter current immunoelectrophoresis (CIEP) method per-
formed on cellulose acetate membranes as formerly described (18).
Results
The antibody preparation that we tested in vitro had the
following properties in vivo. A total of eight Thai patients
were treated by the pool ofPIAG. Six of them at a total dose
of 100 mg/kg over 3 d, and two at a single dose of either
20 mg/kg or 200 mg/kg. In patients treated with 100 mg/kg,
the intravenous inoculation of the Ig preparation was very
well tolerated. Fever disappeared in a mean of 73 h, that is,
as fast or faster than by drug treatment (19) . Parasitemia de-
creased in each case, by an average of 543-fold, and there-
after, remained at low levels for 7-12 d (Fig. 1 a). At 20 mg/kg,
clearance of parasitemia and fever occured fast (68 and 52 h,
respectively), but the lowest parasitaemia reached was higher
than in patients receiving 100 mg/kg(Fig. 1 b). At 200 mg/kg,
parasitemia diminished in two steps. A 160-fold reduction
step occurred in 2 h, together with an intense but transient
spleen reaction, and was followed by a second reduction step
within the next 48 h (Fig. 1 b).
Shown are reciprocal titers obtained usingeither acetone-fixed smears of schizonts of strain Thai B (IFA) or glutaraldehyde (1%)-treated and air-dried
ring-infected RBC (IPA RESA). Results of CIEP are expressed in the number of precipitating bands. Sera are from the patients A to H, taken
on day 0, that is, before PIAG injection.
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During the follow-up, as the transferred Ig were elimi-
nated, parasitemia reincreased progressively. In three cases,
the PIRG was injected a second time (at a rate of 100 mg/kg
dailyfor 2 d) to determine ifthe first injection may have selected
for a parasite populationwith different antigenic features. In
each of the three cases, parasitemia decreased by a mean of
1,310-fold (Fig. 1 c). In contrast, in the control group of 40
patients, who were also recrudescent cases afterquinine failure
but were not treated with PIAG, parasitemia increased up
to 53,000/mm3 before or shortly after receiving Fansimef.
In onecontrol patient, control IgG from healthy French blood
donors was given at 100 mg/kg and parasitemia remained
fluctuating between 8,000 and 12,000/mm3 for 5 d until
drug treatment was given. Since the 11 treatments performed
with African IgG in eight Thai patients had a consistentclinical
and parasitological effect, it can be concluded that there is
no indication of a major geographic restriction of the an-
tigens target of protective antibodies.
The content in antibodies to P.fakiparum antigens in the
pool of donors and in the receivers' sera was analyzed by IPA
and Western blots. Table 1 shows that the receivers had on
day 0, that is, before IgG transfer, whole antigen IFA titers
at least as high as those of the pooled donors, and that more
than half of them had in fact higher titers. This result is con-
sistent with previous studies demonstrating an absence of
correlation between the results from the IFA assay and the
stateof clinical immunity (20). IFARESA titers were, how-
ever, higher in the African pool than in the receivers, an ex-
pected finding since it has been shown that on average titers
increase with exposure to the disease (21).
Similarly, when Western blots were performed with P.fal-
ciparum blood stage antigens, they revealed the existence of
significant amounts of antibodies to most ofthe parasite poly-
peptides in each of the receiver's serum (Fig. 2). Scanning
of these Western blots was used to measure the area under
the curve and, after integration, to evaluate the totalamounts
of antibodies to parasite polypeptides. As for IFA, results re-
veal, for example, that three patients (Fig. 2, lanes C, D,
and E) had more than twice as much antimalarial antibodies
as the PIAG. From this result, it can be concluded that the
differencebetween donors and receivers was more of a qualita-
tive rather than of a quantitative order. The clearclinical and
parasitological improvement obtained by the injection ofthe
PIAG suggests that this pool and the receivers' Ig differ by
Table 1 .
Sera tested
Anti-P. fakiparum
PIAG
Antibody
A
Levels in PIAG
B
and Thai
C
Patient Sera before
D
Transfer
E F G H
IFA 1,600 1,600 1,600 3,200 51,200 12,800 1,600 3,200 6,400
IFA RESA 250 <5 <5 20 <5 10 <5 <5 80
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a limited number ofcritical antibody specificities. This is par-
ticularly true when one considers that in the blood of pa-
tients receiving a total dose of200 and 20 mg/kg, the PIAG
was in fact diluted at least 10 times and 100 times, respec-
tively, while the receivers' Ig were obviously undiluted.
In vitro studies were undertaken to investigate the biolog-
ical effect of the clinically effective IgG upon the parasites
from seven ofthe eight patients, and upon an unrelated African
isolate. In the merozoite invasion assay, addition of 1, 2.5,
and 5 mg/ml of PIAG (that is, -5, 10, and 20% of the
15
en
E
E
b
original IgG concentration in the donor serum) had no or
only a very moderate influence on the rate ofparasite penetra-
tion in R13C (Table 2).
In a 48-h growth assay, which explored both invasion and
intra-erythrocytic maturation, more surprising results were
recorded. As compared with control medium, with and
without control IgG, the presence of PIAG in the culture
resulted in an improved growth of the African isolate, and
of some of the Thai patients' parasites, while the remaining
were unaflected (Table 2 and Figs. 3 and 4). These results
Monocyte-Antibody Cooperation in Plasmodium falciparum Malania
Figure 1.
￿
Results from in vivo transfer of African
IgG. (a) Geometric mean ofparasitemia in six patients
receiving 100 mg/kg of PIAG over 3 d (20, 30, and
50 mg/kg). Shown are the SI)s applied to the geo-
metric mean. (h) Individual parasitemia oftwo patients
treated (20- and 200-mg/kg single dose). (c) Geometric
mean of parasitaemia in three recrudescent cases
receiving a second 200-mg/kg PIAG treatment over
2 d. SI)s applied to the geometric mean.Figure 2.
￿
Comparative analysis of the antibody content in the African pool (PIAG) and in each of the receivers before Ig transfer (sera A-H on
day 0) by Western blots performed on extract of parasites from patient C, revealed with 1251-labeled anti-human IgG (0) or IgM (/).
were consistent in >12 separate experiments performed with
NF54 isolate, although the intensity of increase varied, and
in two to five experiments performed with each of the pa-
tients strains at 2.5-mg/ml concentration ofPIAG. The same
absence of significant inhibition of parasite growth or inva-
sion was observed in experiments in whichwe used IgG prepa-
Percentage of
10 Parasilsemia
NAG
MN + N IgG
NIgG
MN +PIAG
24 48 72 96
Hours
Figure 3.
￿
Antibody-dependent cellular inhibition assay (ADCI) . %-h
cultures were performed usingP . fakipawn isolate from patientC with
daily medium change, either in the presence (A, +) or absence (p, /)
ofmonocytesfrom healthydonors, using control IgG(A, /) or the African
IgG used in the in vivo transfer experiment (p, +) at a2.5-mg/ml con-
centration in RPMI + 10% human serum medium .
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rations from five other African immune adults, as well as with
IgG preparations from six European primary attack cases (not
shown) . Finally, IgG extracted from the initial samples (day
0) of four of the Thai patients were also ineffective in the
same invasion and growth inhibition assays (not shown) .
In view of the former evidence that IgG may cooperate
efficiently with blood monocytes (5, 6), further investiga-
tions were made using the ADCI assay. In this assay, mono-
cytes from healthy blood donors were present at a ratio of
1:200RBC, andPIAG was used at a 10% concentration (2.5
mg/ml), which is about its initial in vivo concentrationwhen
administered at a rate of 100 mg/kg. In contrast with IgG
alone, a consistent antibody-dependent monocyte inhibitory
effect was recorded in a 48-h assay, with each of the seven
Thai patients' isolate and the African strain (Figs . 3 and 4) .
The SGI, which takes into account the possible nonspecific
effect ofmonocytes or IgG alone, reaches 95% forNF54 and
varies between 50 and 80% for the Thai isolates in a 48-h
assay. An example of an ADCI experiment showing the
growth rate in control and test cultures, from which the SGI
is calculated, is given in Fig . 3. This figure also demonstrates
that when cultures are kept >48 h, with daily medium
changes, the intensity of theADCI effect increases with time.
Results were similar when using in vitro PIAG samples ob-
tained before and after the partial pepsine treatment required
to purify IgG for intravenous use (not shown) . IgG extracted
from five individual African adults on DEAE-trisacryl were
also effective (not shown) . Finally, the SGI was not foundFigure 4.
￿
Summary of the 48-h ADCI assays performed with nineP .,
fakiparum isolates and the African IgG (PIAG) . Results are expressed as
the specific growth inhibition in percent, which takes into account the
possible inhibitory or facilitation effect ofeither cells or antibodies alone.
Results obtained by ADCI appear as blackbars (monocytes + antibodies) .
Controls in the presence of antibodies alone appear as hatched bars (the
negative SGI represents an increase of R,fakiparum growth as compared
with control IgG) . (B-M Thai strains isolated from patients B to H be-
fore PIAG transfer. (CX29) The strain isolated from the Thai patient C
on day 29 after transfer upon recrudescence of parasitemia. (NF54) An
African strain used as control in each experiment .
to be influenced by the presence or absence of complement
in the serum used for culture (not shown) .
The IgG offour patients taken before they were passively
protected were ineffective in the same ADO assay. Results
(Fig. 5) ranged from very slight inhibition (SGI = 5%) to
increase of growth (SGI = -22%) . In contrast, IgG ex-
tracted from day 4 samples of the same patients, that is, 4 d
after receiving 10% of PIAG (100 mg/kg), showed a clear
ADO effect . In this case, in which the protective antibody
was in fact diluted at least 1:20 in the receiver serum, that
is -1:200 in the culture well, the SGI reaches 34 and 46%
(Fig. 5) . Thus, results obtained in theADCI assay using IgG
taken either before or after PIAG in vivo transfer appear to
correlate closely with clinical and parasitological observations.
We did not find a close relationship between the intensity
of inhibition in the ADCI assay and the antibody concentra-
tion (above results and other in vitro assays performed with
1, 5, and 10% IgG; not shown), but such is also the case
for results obtainedin vivo using either 20,100, or 200 mg/kg,
which were not directly dose dependent (though recrudes-
cences occurred earlier at 20 mg/kg than at 100 and 200
mg/kg) .
1638
Table 2 .
￿
Evaluation of the Direct E$ect ofPIAG on
Parasite Invasion and Growth
Invasion assay
￿
Growth assay
(percent final
￿
(percent final
parasitemia) parasitemia)
NF54 is a strain thought to be of African origin . B-H are the parasites
isolated from Thai patients before PIAG transfer . Cx29 is the recrudes-
cent strain in ThaiC patient collected 29 d after the PIAG transfer . PIAG
or control IgG were added, at various concentration, to culture medium
(RPMI plus 10% human serum) . The invasion assay was an 18-h culture
ofhighly synchronized mature schizont-infected erythrocytes at 0.5-2%
of parasitemia . The growth assay was a 48-h culture of asynchronous
parasites,, starting at 0.2-0.5% of parasitemia .
Recrudescent parasites from patient C, taken on day 29
after IgG administration (strain CX29), were found suscep-
tible in vitro to the antibody-dependent monocyte inhibi-
tory effect, as they were in vivo to the sameIgG preparation
(Fig. 4) .
Discussion
The present study was designed to establish a precise corre-
lation between in vivo events and in vitro results. Because
of former drug therapy failure, the patients we studied had
harboured parasites for several weeks and therefore developed
a significant immune response to parasite polypeptides, as
shown by IPA and Western blot assays. The immune response
of the patients to parasite antigens had no or limited clinical
Monocyte-Antibody Cooperation in Plasmodium fakiparum Malaria
Strain
IgG
concentration
Control
IgG PIAG
Control
IgG PIAG
mg/ml
NF54 2.5 1.8 1 .8 2.2 4.4
5 1.8 1.7 2.2 3 .3
B 2.5 1.1 1 3 4
5 1.1 1 ND ND
C 2.5 5.7 7.9 8 .3 9 .6
5 5.7 7.7 8.3 9 .4
D 2.5 2.9 2.5 3.2 3 .2
5 2.9 2.4 ND ND
E 2.5 1 .2 1.2 2.6 2.8
5 1 .2 1.3 ND ND
F 2.5 ND ND 2.4 2.8
G 2 .5 ND ND 1.9 1.8
H 2.5 ND ND 2.9 3.5
Cx29 2.5 9.6 11 .5 1.6 1.5
5 9.8 9.5 ND NDFigure 5 .
￿
Results of 48-h ADO assays with four P . fakiparum Thai
isolates and various IgG preparations. Cultures were performed in pres-
ence of monocytes, inRPMI + 10% human serum supplemented with :
PIAG (2.5 mg/ml) or homologous IgG isolated from the patient's serum
on day 0 before transfer or on day 4 after PIAG transfer. All IgG were
used at final concentrations inRPMI corresponding to 10% of their ini-
tial concentration in the donor's serum.
consequences in vivo. We also used in vitro an antibody prep-
aration that, when allowed to interact with the same para-
sites in vivo, had clear detectable parasitological and clinical
effects. For the first time, this set-up allowed us to precisely
match parasites from each patient, in in vitro conditions, ei-
ther with the antibody preparations that were clinically effiic-
tive, or with those non- or insufficiently effective t;E :on the .
same parasites. This set-up differs from that offormestudiet
where antibodies were from subjects only presumably pro-
tected, based on epidemiological and clinical observations,
and parasite isolates or strains were only presumably similar
to the isolates having infected the antibody donors, but in
which no evidence was available that the antibodies studied
could be effective in vivo on the parasites tested in vitro .
In the context of the source of parasites and antibodies we
studied, and in the in vitro conditions we used, the results
strongly support the conclusion that protective antibodies
have very limited direct effects upon parasite growth and in-
vasion, but rather, act in cooperation with blood monocytes.
Reduction of parasitemia with African adult IgG was con-
sistent in the ADCI assay with each of the patients' isolate,
as it was in vivo, while negative or inconsistent results were
obtained with the patients' initial (nonprotective) antibodies
in theADCI assay, as well aswhen using the protective anti-
bodies without effector cells.
In vitro, a direct inhibition exerted by antibodies has been
frequently reportedwhen usingmAbs and also with sera from
immunized animals (22, 23) . Studies in which wholehuman
sera have been used are difficult to interpret, as the involve-
ment of non-IgG factors can be suspected (6, 24) . Relatively
few studies made with IgG fromimmune subjects are avail-
able. In these studies,; the prevalence of individuals with
blocking IgG was usually low among the subjects studied
(25) . When present, it was found to be strain restricted (26),
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whilepremunition is apparently an immunityeffective against
any isolate. Affinity-purified anti-Pf155/RESA antibodies, and
some of the sera with high titers of the same antibody, were
found effective in blocking merozoite invasion in vitro, though
this activity was not consistent in each of the clinically im-
mune subjects (21, 27) . Using a highlypurified IgG prepara-
tion that proved clinically effective, we did not find a significant
inhibition of invasion and no inhibition of growth. To the
contrary, the PIAG frequently induced (six of eight cases)
an increase of growth that reached 100% in one instance,
when using NF54 parasites . The reasons for this paradoxal
improved growth obtained when adding, in vitro, IgG of
a high degree of purity are not clear . This observation is,
however, reminiscent of similar phenomenons reported with
other stages ofmalaria parasites . An increase in oocysts numbers
was repeatedly obtainedwhen mosquitoes were fed gameto-
cytes in the presence of sera containing antigamete antibodies
(28), as was an increase in sporozoite numbers recorded in
mosquitoes fed gametocytes and andsporozoite antibodies (29) .
An increased growth of the asexual blood stages by poly-
clonal antibodies has also been occasionally reported (25), and
more recently, a mAb that enhances merozoite invasion has
been described (30). That some particular antibodiesmay favor
parasite survival, rather than block it, is thus already
documented . Perhaps more unexpected is the observation that
the same antibody preparation that induced parasite clear-
ance in vivo was also responsible for an improved growth
in vitro in the absence of effector cells.
As much as the in vitro conditions can be relevant to in
vivo situations, these results indicate that the clearance ofpara-
sites observed in vivo upon PIAG transfer is most likely not
due to a direct effect of antibodies on the parasite asexual
cycle, and points toward other modes of action . Anti-
Pf155/RESA antibodies were at a higher titer in the donors
that were in the receivers, but first, considering the dose of
Ig administered, their final concentration in the receivers was
very low (intwo cases, lower than that of the receivers), and
second, they were not found effective in blocking invasion
upon the patients strains, at least in our in vitro conditions .
Preliminary in vitro studies did not show reversal ofparasite
adherence to melanoma cells, and found only inconsistent
inhibition ofadherence (Canques et al ., manuscript in prep-
aration) . Complement did not appear to play a role in a former
study (5), as in this study. Thus, in view of the data collected
in vitro, the involvement of effector cells able to cooperate
with antibody seemed a likely hypothesis. Evidence in favor
ofa monocyte-dependent antibody-mediated protection mech-
anism was first obtained in 1983 (5) . This was confirmed in
further unpublished and published studies (6), which were
also aimed at evaluating the cell types possibly involved. Only
blood monocytes were found effective in ADCI, and other
cells, such as lymphocytes, platelets, polymorphonuclears, and
adherent spleen cells, were not . This antibody-dependent
monoeyte-mediated inhibitory or cytotoxic effect was con-
firmed by others (31) . In the present study, results from the
ADCI assay yielded clear-cut results. There was a direct corre-
lation between the inhibitory effect of a given antibody prep-
aration in this assay and its in vivo potential. Initial antibodiesfrom patients were consistently ineffective in the ADCI assay,
while the African antibodies transferred, and the patients an-
tibodies collected after transfer, were effective. Both initial
and recrudescent parasites were susceptible in vitro in ADCI
as was the case in vivo with the same Ig preparation. Further
in vivo confirmation of the essential role of monocytes ap-
pears difficult to achieve, as it would require the in vivo deple-
tion of this cell subset, which, obviously, cannot be envisaged
in the natural model.
Based on the correlation found, in the former (5) and in
the present study, between the status of acquired protection
and the ability of antibodies to cooperate with blood mono-
cytes, we conclude that the ADCI assay can be proposed as
one means to select for antigen targets of antibody-mediated
mechanisms. Malaria parasite polymorphism is an increas-
ingly evident feature emerging from the characterization of
several P. falciparum antigens (32). In the seven isolates we
studied, this polymorphism was found to concern at least
30% of the polypeptides revealed by the African IgG pool
in Western blots performed with extracts from each patient's
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